Acrivon Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Acrivon Therapeutics, Inc. on June 20, 2024. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Watertown, Massachusetts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
A quorum of 27,422,027 shares (88.81% of outstanding shares) was present or represented by proxy. Two proposals were acted upon:
- Proposal One (Election of Directors): Kristina Masson, Sharon Shacham, and Ivana Magovčević-Liebisch were elected as Class II Directors to serve until the 2027 Annual Meeting.
- Proposal Two (Ratification of Auditors): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verification of the specific vote counts for each director nominee, noting significant broker non-votes.
- Confirmation of the ratification of PricewaterhouseCoopers LLP as the auditor for the 2024 fiscal year.
- Review of the company's latest 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.